Psychedelics

Texas Gov. Greg Abbott (R) has signed a bill dedicating up to $100 million toward researching ibogaine, a naturally occurring psychedelic that shows promise as a treatment for depression, anxiety, and PTSD.

The Colorado medical psilocybin program is nearly set to launch after officials tested and inspected a testing facility, which was the last type of business required to properly run the program.

Researchers at UC Davis say they have developed an analog of LSD named JRT that encourages neuroplasticity without psychedelic side effects, and could be an effective treatment for schizophrenia.

A proposal filed in the Nevada Assembly would establish a psychedelics therapy program for certain patients with mental health conditions.

Lawmakers in the Missouri House Committee on Veterans and Armed Forces voted unanimously to advance a bill establishing clinical trials testing the effectiveness of medical psilocybin as a treatment for PTSD and other conditions.

The Tacoma, Washington City Council has unanimously passed a resolution to make prosecutions for entheogenic psychedelics the lowest priority for law enforcement.

Lawmakers in a Virginia Senate committee have advanced a bill funding clinical trials to investigate federally recognized “breakthrough therapies” for veterans’ mental health issues, including psychedelic substances like MDMA and psilocybin.

Massachusetts voters rejected the state’s medical psychedelics legalization ballot initiative with 57% opposed and 43% in favor. The proposal sought to legalize the medical use of psilocybin, psilocin, dimethyltryptamine (DMT), ibogaine, and mescaline for patients aged 21+.

Activists in Portland, Oregon are planning to pursue a ballot initiative in 2026 to decriminalize natural psychedelics including psilocybin mushrooms and ayahuasca after lawmakers this year voted to undo the state’s voter-approved drug decriminalization policy.

The DEA is proposing revised 2024 and new 2025 production quotas for research-grade psychedelics including psilocybin, psilocin, and ibogaine. The agency says the new production rates are needed to drive new research.

Colorado officials recently released the state’s final regulations for its medicinal psilocybin program. Under the rules, psychedelic therapy centers will be cleared to open for business starting next year.

The head of UCLA’s Semel Institute for Neuroscience and Human Behavior is aiming to convert the institute’s top floor into a rooftop garden, or “living laboratory,” designed to study and facilitate psychedelic-assisted therapy.

Massachusetts officials have confirmed that voters will decide this November whether to legalize psychedelics including DMT, mescaline, ibogaine, psilocybin, and psilocin for adults aged 21+.

Researchers analyzing data from the Midlife in the United States (MIDUS) study recently found that older adults who have used psychedelics tend to exhibit better cognitive function and fewer depressive symptoms.

The Department of Veterans Affairs (VA) could finally let veterans participate in state-legal medical cannabis programs under a House-approved amendment to the Military Construction, Veterans Affairs, and Related Agencies (MilConVA) Fiscal Year 2024 Appropriations Bill.

In a review of the hallucinogen MDMA posted last week, the FDA highlighted concerns about the initial investigations into the drug as a potential new therapy for the treatment of post-traumatic stress disorder (PTSD).

Following the recent failure of a state bid to legalize psychedelic treatment centers in California, advocates now say they are considering a 2026 state ballot measure to address psychedelics reform.

The proposal to legalize psychedelic treatment centers in California has failed for the year. The proposal was crafted in response to concerns raised by Gov. Gavin Newsom (D) last year after he vetoed a different proposal to decriminalize certain naturally occurring psychedelics.

The publicly traded and internationally licensed cannabis company Kaya Holdings Inc. announced this week that it has received a license to administer therapeutic psilocybin products in Oregon.

According to a new study compiled by UK researchers, psilocybin — the naturally occurring psychedelic in so-called “magic mushrooms” — shows promise as an effective treatment for depression.

California lawmakers in the Senate Public Safety Committee voted to advance a proposal that would establish treatment centers where adults aged 21+ could access psilocybin, MDMA, DMT, and other psychedelics.

A bipartisan Wisconsin proposal is seeking to make it easier for researchers to treat patients with post-traumatic stress disorder with psilocybin.